Dr. Jun on Results of Study in Cryptogenic Hepatocellular Carcinoma

Tomi Jun, MD
Published: Friday, Apr 21, 2017



Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma (HCC).

This was a multi-center, international cohort of about 4000 patients out of the United States and Taiwan that aimed to evaluate the significantly lower rates of cirrhosis and worse long-term survival in patients with cryptogenic HCC compared with viral etiologies.

Although patients with cryptogenic HCC showed less cirrhosis, survival was significantly lower than what was shown in patients with hepatitis b- and hepatitis c-related HCC.
 

<<< View more from the 2017 International Liver Congress



Tomi Jun, MD, Stanford University School of Medicine, discusses the results of a study of cirrhosis and long-term survival in patients with cryptogenic hepatocellular carcinoma (HCC).

This was a multi-center, international cohort of about 4000 patients out of the United States and Taiwan that aimed to evaluate the significantly lower rates of cirrhosis and worse long-term survival in patients with cryptogenic HCC compared with viral etiologies.

Although patients with cryptogenic HCC showed less cirrhosis, survival was significantly lower than what was shown in patients with hepatitis b- and hepatitis c-related HCC.
 

<<< View more from the 2017 International Liver Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x